Niiki Pharma Inc.


HOBOKEN, New Jersey and PHILADELPHIA, September 20, 2011 - Niiki Pharma Inc.

HOBOKEN, New Jersey and PHILADELPHIA, June 1, 2011 - - Phase I Data for NKP-1339, a First-in-Class Transferrin Targeted Anti-Cancer Agent to be Presented at Upcoming American Society of Clinical Oncology Annual Meeting Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL.
Older News
S M T W T F S
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
Copyright© 2011 The Gaea Times